Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.

Jin Qian, PhD, associate research scientist, Department of Medicine, Digestive & Liver Diseases, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses preclinical findings for a secreted CXCR4 partial agonist called trefoil factor family 2 (TFF2) in combination with anti–PD-1 therapy in advanced gastric cancer refractory to PD-1 blockade.

The study utilized a novel TFF2-MSA peptide with extended half-life, generated by fusing mouse TFF2 with murine serum albumin. Therapeutic effects were evaluated both in vitro and in vivo, utilizing HDC-GFP transgenic mice to track polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), which highly express CXCR4.

 demonstrated that the combination of TFF2-MSA and anti–PD-1 antibody exhibited synergy, significantly boosting intratumoral cytotoxic CD8-positive T cells, leading to tumor regression or eradication, reduction of distant metastases, and extension of mouse survival. Importantly, TFF2-MSA treatment systematically reduced HDC-GFP–positive PMN-MDSCs in various components, including tumor, blood, spleen, and bone marrow myeloid progenitors.

Qian notes that further analyses revealed that TFF2-MSA plus anti–PD-1 therapy induced a shift in the composition of tumor HDC-GFP–positive PMN-MDSCs toward less immature subsets expressing interferon-stimulated genes, thereby reducing immunosuppression and enhancing antigen presentation functions. This shift was driven by an IRF1-mediated interferon response in splenic HDC-GFP–positive PMN-MDSCs. In contrast, the CXCR4 antagonist AMD3100, in combination with anti–PD-1, failed to restrict tumor growth or PMN-MDSCs.

Overall, these findings suggest that TFF2-MSA synergizes with PD-1 blockade by selectively targeting PMN-MDSCs with high CXCR4 expression, providing a rationale for further investigation of this novel combination therapy approach in advanced gastric cancer, Qian concludes.

Videos

Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.

Jin Qian, PhD

Articles

Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.